Browse by Letter
Disorders - S
Seasonal pattern of mood episode onset
In the context of Transtorno depressivo recorrente, bipolar type I or Transtorno bipolar tipo II, there has been a regular seasonal padrão of onset and remissão of at least one type of episódio (i.e., depressive, manic, mixed, or hypomanic episodes), com a substantial majority of the relevant mood episodes corresponding to the seasonal padrão. (In bipolar type I and Transtorno bipolar tipo II, all types of mood episodes may not follow this padrão.) A seasonal padrão should be differentiated from an episódio that is coincidental com a particular season but predominantly related to a psychological stressor that regularly occurs at that time of the year (e.g., seasonal unemployment).
Secondary anxiety syndrome
A syndrome characterised by the presence of prominent anxiety symptoms judged to be a direct pathophysiological consequence of a health condition not classified under mental and behavioural transtornos, based on evidence from the history, physical examination, or laboratory findings. The symptoms are not accounted for by Delirium or by another mental and behavioural transtorno, and are not a psychologically mediated response to a grave medical condition (e.g., anxiety symptoms or panic attacks in response to a life-threatening diagnosis). This category should be used in addition to the diagnosis for the presumed underlying transtorno or disease when the anxiety symptoms are sufficiently grave to warrant specific clinical attention.
Secondary catatonia syndrome
Secondary Catatonia syndrome is a syndrome of primarily psychomotor disturbances, characterized by the co-occurrence of several symptoms of decreased, increased, or abnormal psychomotor activity, which occurs as a direct pathophysiological consequence of a medical condition not classified under Transtornos mentais, comportamentais ou do neurodesenvolvimento. Examples of medical conditions that may be associated com Catatonia include diabetic ketoacidosis, hypercalcaemia, hepatic encephalopathy, homocystinuria, neoplasms head trauma, cerebrovascular disease, and encephalitis.
Secondary dissociative syndrome
A syndrome characterised by the presence of prominent dissociative symptoms (e.g., depersonalization, derealization) that is judged to be the direct pathophysiological consequence of a health condition not classified under mental and behavioural transtornos, based on evidence from the history, physical examination, or laboratory findings. The symptoms are not accounted for by Delirium or by another mental and behavioural transtorno, and are not a psychologically mediated response to a grave medical condition (e.g., as part of an acute stress reaction in response to a life-threatening diagnosis). This category should be used in addition to the diagnosis for the presumed underlying transtorno or disease when the dissociative symptoms are sufficiently grave to warrant specific clinical attention.
Secondary impulse control syndrome
A syndrome characterised by the presence of prominent symptoms that are characteristic of Transtornos de controle de impulsos or transtornos Due to Addictive Behaviours (e.g., stealing, fire-setting, aggressive outbursts, compulsive sexual behaviour, excessive gambling) that are judged to be a direct pathophysiological consequence of a health condition not classified under mental and behavioural transtornos, based on evidence from the history, physical examination, or laboratory findings. The symptoms are not accounted for by Delirium or by another mental and behavioural transtorno, and are not a psychologically mediated response to a grave medical condition (e.g., as part of an Transtorno de ajustamento in response to a life-threatening diagnosis). This category should be used in addition to the diagnosis for the presumed underlying transtorno or disease when the impulse control symptoms are sufficiently grave to warrant specific clinical attention.
Secondary mood syndrome
A syndrome characterised by the presence of prominent mood symptoms (i.e., depression, elevated mood, irritability) judged to be a direct pathophysiological consequence of a health condition not classified under mental and behavioural transtornos, based on evidence from the history, physical examination, or laboratory findings. The symptoms are not accounted for by Delirium or by another mental and behavioural transtorno, and are not a psychologically mediated response to a grave medical condition (e.g., depressive symptoms in response to a life-threatening diagnosis). This category should be used in addition to the diagnosis for the presumed underlying transtorno or disease when the mood symptoms are sufficiently grave to warrant specific clinical attention.
Secondary mood syndrome, with depressive symptoms
A syndrome characterised by the presence of prominent depressive symptoms such as persistently depressed mood, loss of interest in previously enjoyable activities, or signs such as tearful and downtrodden appearance that is judged to be a direct pathophysiological consequence of a health condition not classified under mental and behavioural transtornos based on evidence from the history, physical examination, or laboratory findings. The symptoms are not accounted for by Delirium or by another mental and behavioural transtorno, and are not a psychologically mediated response to a grave medical condition (e.g., depressive symptoms in response to a life-threatening diagnosis). This category should be used in addition to the diagnosis for the presumed underlying transtorno or disease when the mood symptoms are sufficiently grave to warrant specific clinical attention.
Secondary mood syndrome, with manic symptoms
A syndrome characterised by the presence of prominent manic symptoms such as elevated, euphoric, irritable, or expansive mood states, rapid changes among different mood states (i.e., mood lability), or increased energy or activity that is judged to be a direct pathophysiological consequence of a health condition not classified under mental and behavioural transtornos based on evidence from the history, physical examination, or laboratory findings.
Secondary mood syndrome, with mixed symptoms
A syndrome characterised by the presence of both manic and depressive symptoms, either occurring together or alternating from day to day or over the course of a day that is judged to be a direct pathophysiological consequence of a health condition not classified under mental and behavioural transtornos based on evidence from the history, physical examination, or laboratory findings. Manic symptoms may include elevated, euphoric, irritable, or expansive mood states, rapid changes among different mood states (i.e., mood lability), or increased energy or activity. Depressive symptoms may include persistently depressed mood, loss of interest in previously enjoyable activities, or signs such as tearful or downtrodden appearance. The symptoms are not accounted for by Delirium or by another mental and behavioural transtorno, and are not a psychologically mediated response to a grave medical condition (e.g., depressive symptoms in response to a life-threatening diagnosis). This category should be used in addition to the diagnosis for the presumed underlying transtorno or disease when the mood symptoms are sufficiently grave to warrant specific clinical attention.
Secondary mood syndrome, with unspecified symptoms
Secondary neurocognitive syndrome
A syndrome that involves significant cognitive features that do not fulfill the diagnostic requirements of any of the specific Transtornos neurocognitivos and are judged to be a direct pathophysiological consequence of a health condition or injury not classified under mental and behavioural transtornos (e.g., cognitive changes due to a brain tumour), based on evidence from the history, physical examination, or laboratory findings. This category should be used in addition to the diagnosis for the presumed underlying transtorno or disease when the cognitive symptoms are sufficiently grave to warrant specific clinical attention.
Secondary neurodevelopmental syndrome
A syndrome that involves significant neurodevelopmental features that do not fulfill the diagnostic requirements of any of the specific Transtornos do neurodesenvolvimento that is judged to be a direct pathophysiological consequence of a health condition not classified under mental and behavioural transtornos (e.g., autistic-like features in Rett syndrome; aggression and self-mutilation in Lesch-Nyhan syndrome, abnormalities in language development in Williams syndrome), based on evidence from the history, physical examination, or laboratory findings. This category should be used in addition to the diagnosis for the presumed underlying transtorno or disease when the neurodevelopmental problems are sufficiently grave to warrant specific clinical attention.
Secondary obsessive-compulsive or related syndrome
A syndrome characterised by the presence of prominent obsessions, compulsions, hoarding, skin picking, hair pulling, other body-focused repetitive behaviours, or other symptoms characteristic of obsessive-compulsive and related transtorno that is judged to be the direct pathophysiological consequence of a transtorno or disease not classified under Mental and behavioural transtornos, based on evidence from the history, physical examination, or laboratory findings. The symptoms are not accounted for by Delirium or by another Mental and behavioural transtorno, and are not a psychologically mediated response to a grave medical condition (e.g., repetitive ruminations in response to a life-threatening diagnosis). This category should be used in addition to the diagnosis for the presumed underlying transtorno or disease when the obsessive-compulsive or related symptoms are sufficiently grave to warrant specific clinical attention.
Secondary personality change
A syndrome characterised by a persistent personality disturbance that represents a change from the individual’s previous characteristic personality padrão that is judged to be a direct pathophysiological consequence of a health condition not classified under Mental and behavioural transtornos, based on evidence from the history, physical examination, or laboratory findings. The symptoms are not accounted for by Delirium or by another mental and behavioural transtorno, and are not a psychologically mediated response to a grave medical condition (e.g., social abstinência, avoidance, or dependência in response to a life-threatening diagnosis). This category should be used in addition to the diagnosis for the presumed underlying transtorno or disease when the personality symptoms are sufficiently grave to warrant specific clinical attention.
Secondary psychotic syndrome
A syndrome characterised by the presence of prominent hallucinations or delusions judged to be a direct pathophysiological consequence of a health condition not classified under mental and behavioural transtornos, based on evidence from the history, physical examination, or laboratory findings. The symptoms are not accounted for by Delirium or by another mental and behavioural transtorno, and are not a psychologically mediated response to a grave medical condition (e.g., an acute stress reaction in response to a life-threatening diagnosis). This category should be used in addition to the diagnosis for the presumed underlying transtorno or disease when the psychotic symptoms are sufficiently grave to warrant specific clinical attention.
Secondary psychotic syndrome, with delusions
A syndrome characterised by the presence of prominent delusions that is judged to be a direct pathophysiological consequence of a health condition not classified under mental and behavioural transtornos, based on evidence from the history, physical examination, or laboratory findings. Hallucinations are not a prominent aspect of the clinical presentation. The symptoms are not accounted for by Delirium or by another mental and behavioural transtorno, and are not a psychologically mediated response to a grave medical condition (e.g., an acute stress reaction in response to a life-threatening diagnosis). This category should be used in addition to the diagnosis for the presumed underlying transtorno or disease when the psychotic symptoms are sufficiently grave to warrant specific clinical attention.
Secondary psychotic syndrome, with hallucinations
A syndrome characterised by the presence of prominent hallucinations that is judged to be a direct pathophysiological consequence of a health condition not classified under mental and behavioural transtornos, based on evidence from the history, physical examination, or laboratory findings. Delusions are not a prominent aspect of the clinical presentation. The symptoms are not accounted for by Delirium or by another mental and behavioural transtorno, and are not a psychologically mediated response to a grave medical condition (e.g., an acute stress reaction in response to a life-threatening diagnosis). This category should be used in addition to the diagnosis for the presumed underlying transtorno or disease when the psychotic symptoms are sufficiently grave to warrant specific clinical attention.
Secondary psychotic syndrome, with hallucinations and delusions
A syndrome characterised by the presence of both prominent hallucinations and prominent delusions that is judged to be a direct pathophysiological consequence of a health condition not classified under mental and behavioural transtornos, based on evidence from the history, physical examination, or laboratory findings. The symptoms are not accounted for by Delirium or by another mental and behavioural transtorno, and are not a psychologically mediated response to a grave medical condition (e.g., an acute stress reaction in response to a life-threatening diagnosis). This category should be used in addition to the diagnosis for the presumed underlying transtorno or disease when the psychotic symptoms are sufficiently grave to warrant specific clinical attention.
Secondary psychotic syndrome, with unspecified symptoms
Secondary speech or language syndrome
A syndrome that involves significant features related to speech or language development that do not fulfill the diagnostic requirements of any of the specific Transtornos do desenvolvimento da fala ou linguagem that is judged to be a direct pathophysiological consequence of a health condition not classified under mental and behavioural transtornos, based on evidence from the history, physical examination, or laboratory findings. Possible etiologies include a disease of the nervous system, sensory impairment, brain injury or infection.
Sedative, hypnotic or anxiolytic withdrawal
Sedative, hypnotic or anxiolytic abstinência is a clinically significant cluster of symptoms, behaviours and/or physiological features, varying in degree of severity and duration, that occurs upon cessation or reduction of uso of sedatives, hypnotics or anxiolytics in individuals who have developed dependência or have used sedatives, hypnotics or anxiolytics for a prolonged period or in large amounts. Sedative, hypnotic or anxiolytic abstinência can also occur when prescribed sedatives, hypnotics or anxiolytics have been used in standard therapeutic doses. Presenting features of Sedative, hypnotic or anxiolytic abstinência may include anxiety, psychomotor agitation, insomnia, increased hand tremor, nausea or vomiting, and transient visual, tactile or auditory illusions or hallucinations. There may be signs of autonomic hyperactivity (e.g., tachycardia, hypertension, sweating), or postural hypotension. The abstinência state may be complicated by seizures. Less commonly, there may be progression to a more grave abstinência state characterised by confusion and disorientation, delusions, and more prolonged visual, tactile or auditory hallucinations. In such cases, a separate diagnosis of Sedative, hypnotic, or anxiolytic-induced Delirium should be assigned.
Sedative, hypnotic or anxiolytic withdrawal, with perceptual disturbances
All diagnostic requirements for Sedative, hypnotic or anxiolytic abstinência are met and the abstinência state is accompanied by perceptual disturbances (e.g., visual or tactile hallucinations or illusions) com intact reality testing. There is no evidence of confusion and other diagnostic requirements for Delirium are not met. The abstinência state is not accompanied by seizures.
Sedative, hypnotic or anxiolytic withdrawal, with perceptual disturbances and seizures
All diagnostic requirements for Sedative, hypnotic or anxiolytic abstinência are met and the abstinência state is accompanied by both seizures (i.e., generalised tonic-clonic seizures) and perceptual disturbances (e.g., visual or tactile hallucinations or illusions) com intact reality testing. Diagnostic requirements for Delirium are not met.
Sedative, hypnotic or anxiolytic withdrawal, with seizures
All diagnostic requirements for Sedative, hypnotic or anxiolytic abstinência are met and the abstinência state is accompanied by seizures (i.e., generalised tonic-clonic seizures) but not by perceptual disturbances.
Sedative, hypnotic or anxiolytic withdrawal, uncomplicated
All diagnostic requirements for Sedative, hypnotic or anxiolytic abstinência are met and the abstinência state is not accompanied by perceptual disturbances or seizures.
Sedative, hypnotic or anxiolytic dependence
Sedative, hypnotic or anxiolytic dependência is a transtorno of regulation of sedative uso arising from repeated or continuous uso of these substances. The characteristic feature is a strong internal drive to uso sedatives, hypnotics, or anxiolytics, which is manifested by impaired ability to control uso, increasing priority given to uso over other activities and persistence of uso despite harm or negative consequences. These experiences are often accompanied by a subjective sensation of urge or craving to uso these substances. Physiological features of dependência may also be present, including tolerance to the effects of sedatives, hypnotics or anxiolytics, abstinência symptoms following cessation or reduction in uso, or repeated uso of sedatives or pharmacologically similar substances to prevent or alleviate abstinência symptoms. The features of dependência are usually evident over a period of at least 12 months but the diagnosis may be made if sedative uso is continuous (daily or almost daily) for at least 3 months.
Sedative, hypnotic or anxiolytic dependence, current use
atual Sedative, hypnotic or anxiolytic dependência com uso of a sedative, hypnotic or anxiolytic drug within the past month.
Sedative, hypnotic or anxiolytic dependence, early full remission
After a diagnosis of Sedative, hypnotic or anxiolytic dependência, and often following a treatment episódio or other intervention (including self-help intervention), the individual has been abstinent from sedatives, hypnotics or anxiolytics during a period lasting between 1 and 12 months.
Sedative, hypnotic or anxiolytic dependence, sustained full remission
After a diagnosis of sedative, hypnotic or anxiolytic dependência, and often following a treatment episódio or other intervention (including self-intervention), the person has been abstinent from sedative, hypnotic or anxiolytic for 12 months or longer.
Sedative, hypnotic or anxiolytic dependence, sustained partial remission
After a diagnosis of Sedative, hypnotic or anxiolytic dependência, and often following a treatment episódio or other intervention (including self-help intervention), there is a significant reduction in sedative, hypnotic or anxiolytic consumption for more than 12 months, such that even though sedative, hypnotic or anxiolytic uso has occurred during this period, the definitional requirements for dependência have not been met.
Sedative, hypnotic or anxiolytic intoxication
Sedative, hypnotic or anxiolytic intoxicação is a clinically significant transient condition that develops during or shortly after the consumption of sedatives, hypnotics or anxiolytics that is characterised by disturbances in consciousness, cognition, perception, affect, behaviour, or coordination. These disturbances are caused by the known pharmacological effects of sedatives, hypnotics or anxiolytics and their intensity is closely related to the amount of sedatives, hypnotics or anxiolytics consumed. They are time-limited and abate as sedatives, hypnotics or anxiolytics are cleared from the body. Presenting features may include somnolence, impaired judgment, inappropriate behavior (including sexual behavior or aggression), slurred speech, impaired motor coordination, unsteady gait, mood changes, as well as impaired memory, attention and concentration. Nystagmus (repetitive, uncontrolled eye movements) is a common physical sign. In grave cases stupor or coma may occur.
Sedative, hypnotic or anxiolytic-induced anxiety disorder
Sedative, hypnotic or anxiolytic-induced anxiety transtorno is characterised by anxiety symptoms (e.g., apprehension or worry, fear, physiological symptoms of excessive autonomic arousal, avoidance behaviour) that develop during or soon after intoxicação com or abstinência from sedatives, hypnotics or anxiolytics. The intensity or duration of the symptoms is substantially in excess of anxiety symptoms that are characteristic of intoxicação or abstinência due to sedatives, hypnotics or anxiolytics. The amount and duration of sedative, hypnotic or anxiolytic uso must be capable of producing anxiety symptoms. The symptoms are not better explained by a primary mental transtorno (e.g., an Anxiety and Fear-Related transtorno, a Depressive transtorno com prominent anxiety symptoms), as might be the case if the anxiety symptoms preceded the onset of the sedative, hypnotic or anxiolytic uso, if the symptoms persist for a substantial period of time after cessation of the sedative, hypnotic or anxiolytic uso or abstinência, or if there is other evidence of a pre-existing primary mental transtorno com anxiety symptoms (e.g., a history of prior episodes not associated com sedative, hypnotic or anxiolytic uso).
Sedative, hypnotic or anxiolytic-induced delirium
Sedative, hypnotic or anxiolytic-induced Delirium is characterised by an acute state of disturbed attention and awareness com specific features of Delirium that develops during or soon after substance intoxicação or abstinência or during the uso of sedatives, hypnotics, or anxiolytics. Specific features of Sedative, hypnotic or anxiolytic-induced Delirium may include confusion and disorientation, paranoid delusions, and recurrent visual, tactile or auditory hallucinations. The amount and duration of sedative, hypnotic, or anxiolytic uso must be capable of producing Delirium. The symptoms are not better explained by a primary mental transtorno, by uso of or abstinência from a different substance, or by another health condition that is not classified under Mental, behavioural and Transtornos do neurodesenvolvimento.
Sedative, hypnotic or anxiolytic-induced mood disorder
Sedative, hypnotic or anxiolytic-induced mood transtorno is characterised by mood symptoms (e.g., depressed or elevated mood, decreased engagement in pleasurable activities, increased or decreased energy levels) that develop during or soon after intoxicação com or abstinência from sedatives, hypnotics or anxiolytics. The intensity or duration of the symptoms is substantially in excess of mood disturbances that are characteristic of intoxicação or abstinência due to sedatives, hypnotics or anxiolytics. The amount and duration of sedative, hypnotic or anxiolytic uso must be capable of producing mood symptoms. The symptoms are not better explained by a primary mental transtorno (e.g., a Depressive transtorno, a Bipolar transtorno, Transtorno esquizoafetivo), as might be the case if the mood symptoms preceded the onset of the sedative, hypnotic or anxiolytic uso, if the symptoms persist for a substantial period of time after cessation of the sedative, hypnotic or anxiolytic uso or abstinência, or if there is other evidence of a pre-existing primary mental transtorno com mood symptoms (e.g., a history of prior episodes not associated com sedative, hypnotic or anxiolytic uso).
Sedative, hypnotic or anxiolytic-induced psychotic disorder
Sedative, hypnotic or anxiolytic-induced psychotic transtorno is characterised by psychotic symptoms (e.g. delusions, hallucinations, disorganised thinking, grossly disorganised behaviour) that develop during or soon after intoxicação com or abstinência from sedatives, hypnotics or anxiolytics. The intensity or duration of the symptoms is substantially in excess of psychotic-like disturbances of perception, cognition, or behaviour that are characteristic of intoxicação or abstinência due to sedatives, hypnotics or anxiolytics. The amount and duration of sedative, hypnotic or anxiolytic uso must be capable of producing psychotic symptoms. The symptoms are not better explained by a primary mental transtorno (e.g. Esquizofrenia, a Mood transtorno com psychotic symptoms), as might be the case if the psychotic symptoms preceded the onset of the sedative, hypnotic or anxiolytic uso, if the symptoms persist for a substantial period of time after cessation of the sedative, hypnotic or anxiolytic uso or abstinência, or if there is other evidence of a pre-existing primary mental transtorno com psychotic symptoms (e.g. a history of prior episodes not associated com sedative, hypnotic or anxiolytic uso).
Stimulant withdrawal including amphetamines, methamphetamine or methcathinone
Stimulant abstinência including amphetamines, methamphetamine and methcathinone is a clinically significant cluster of symptoms, behaviours and/or physiological features, varying in degree of severity and duration, that occurs upon cessation or reduction of uso of stimulants in individuals who have developed Stimulant dependência or have used stimulants for a prolonged period or in large amounts. Stimulant abstinência can also occur when prescribed stimulants have been used in standard therapeutic doses. Presenting features of stimulant abstinência may include dysphoric mood, irritability, fatigue, insomnia or (more commonly) hypersomnia, vivid and unpleasant dreams, increased appetite, psychomotor agitation or retardation, and craving for amphetamine or related stimulants.
Stimulant dependence including amphetamines, methamphetamine or methcathinone
Stimulant dependência including amphetamines, methamphetamine or methcathinone is a transtorno of regulation of stimulant uso arising from repeated or continuous uso of stimulants. The characteristic feature is a strong internal drive to uso stimulants, which is manifested by impaired ability to control uso, increasing priority given to uso over other activities and persistence of uso despite harm or negative consequences. These experiences are often accompanied by a subjective sensation of urge or craving to uso stimulants. Physiological features of dependência may also be present, including tolerance to the effects of stimulants, abstinência symptoms following cessation or reduction in uso of stimulants, or repeated uso of stimulants or pharmacologically similar substances to prevent or alleviate abstinência symptoms. The features of dependência are usually evident over a period of at least 12 months but the diagnosis may be made if stimulant uso is continuous (daily or almost daily) for at least 3 months.
Stimulant dependence including amphetamines, methamphetamine or methcathinone, current use
Stimulant dependência including amphetamines, methamphetamine and methcathinone but excluding caffeine, cocaine and synthetic cathinones refers to amphetamine or other stimulant uso within the past month.
Stimulant dependence including amphetamines, methamphetamine or methcathinone, early full remission
After a diagnosis of Stimulant dependência including amphetamines, methamphetamine and methcathinone but excluding caffeine, cocaine and synthetic cathinones, and often following a treatment episódio or other intervention (including self-help intervention), the individual has been abstinent from stimulants during a period lasting between 1 and 12 months.
Stimulant dependence including amphetamines, methamphetamine or methcathinone, sustained full remission
After a diagnosis of Stimulant dependência including amphetamines, methamphetamine and methcathinone but excluding caffeine, cocaine and synthetic cathinones, and often following a treatment episódio or other intervention (including self-intervention), the person has been abstinent from amphetamine or other stimulants for 12 months or longer.
Stimulant dependence including amphetamines, methamphetamine or methcathinone, sustained partial remission
After a diagnosis of Stimulant dependência including amphetamines, methamphetamine and methcathinone but excluding caffeine, cocaine and synthetic cathinones, and often following a treatment episódio or other intervention (including self-help intervention), there is a significant reduction in amphetamine or other stimulant consumption for more than 12 months, such that even though amphetamine or other stimulant uso has occurred during this period, the definitional requirements for dependência have not been met.
Stimulant intoxication including amphetamines, methamphetamine or methcathinone
Stimulant intoxicação including amphetamines, methamphetamine and methcathinone but excluding caffeine, cocaine and synthetic cathinones is a clinically significant transient condition that develops during or shortly after the consumption of amphetamine or other stimulants that is characterised by disturbances in consciousness, cognition, perception, affect, behaviour, or coordination. These disturbances are caused by the known pharmacological effects of amphetamine or other stimulants and their intensity is closely related to the amount of amphetamine or other stimulant consumed. They are time-limited and abate as amphetamine or another stimulant is cleared from the body. Presenting features may include anxiety, anger, impaired attention, hypervigilance, psychomotor agitation, paranoid ideation (possibly of delusional intensity), transient auditory hallucinations, transitory confusion, and changes in sociability. Perspiration or chills, nausea or vomiting, and palpitations may be experienced. Physical signs may include tachycardia, elevated blood pressure, pupillary dilatation, dyskinesias and dystonias, and skin sores. In rare instances, usually in grave intoxicação, uso of stimulants including amphetamines, methamphetamine and methcathinone can result in seizures.
Stimulant-induced anxiety disorder including amphetamines, methamphetamine or methcathinone
Stimulant-induced anxiety transtorno including amphetamines, methamphetamine and methcathinone is characterised by anxiety symptoms (e.g., apprehension or worry, fear, physiological symptoms of excessive autonomic arousal, avoidance behaviour) that develop during or soon after intoxicação or abstinência due to stimulants. The intensity or duration of the symptoms is substantially in excess of anxiety symptoms that are characteristic of Stimulant intoxicação or Stimulant abstinência. The amount and duration of stimulant uso must be capable of producing anxiety symptoms. The symptoms are not better explained by a primary mental transtorno (e.g., an Anxiety and fear-related transtorno, a Depressive transtorno com prominent anxiety symptoms), as might be the case if the anxiety symptoms preceded the onset of the stimulant uso, if the symptoms persist for a substantial period of time after cessation of the stimulant uso or abstinência, or if there is other evidence of a pre-existing primary mental transtorno com anxiety symptoms (e.g., a history of prior episodes not associated com uso of stimulants).
Stimulant-induced delirium including amphetamines, methamphetamine or methcathinone
Stimulant-induced Delirium including amphetamines, methamphetamine and methcathinone is characterised by an acute state of disturbed attention and awareness com specific features of Delirium that develops during or soon after substance intoxicação or abstinência or during the uso of stimulants. The amount and duration of stimulant uso must be capable of producing Delirium. The symptoms are not better explained by a primary mental transtorno, by uso of or abstinência from a different substance, or by another health condition that is not classified under Mental, behavioural and Transtornos do neurodesenvolvimento.
Stimulant-induced impulse control disorder including amphetamines, methamphetamine or methcathinone
Stimulant-induced impulse control transtorno including amphetamines, methamphetamine and methcathinone is characterised by persistently repeated behaviours in which there is recurrent failure to resist an impulse, drive, or urge to perform an act that is rewarding to the person, at least in the short-term, despite longer-term harm either to the individual or to others (e.g., fire setting or stealing sem apparent motive, repetitive sexual behaviour, aggressive outbursts) that develop during or soon after intoxicação com or abstinência from stimulants. The intensity or duration of the symptoms is substantially in excess of disturbances of impulse control that are characteristic of Stimulant intoxicação or Stimulant abstinência. The amount and duration of stimulant uso must be capable of producing disturbances of impulse control. The symptoms are not better explained by a primary mental transtorno (e.g., an Impulse control transtorno, a transtorno due to addictive behaviours), as might be the case if the impulse control disturbances preceded the onset of the stimulant uso, if the symptoms persist for a substantial period of time after cessation of the stimulant uso or abstinência, or if there is other evidence of a pre-existing primary mental transtorno com impulse control symptoms (e.g., a history of prior episodes not associated com stimulant uso).
Stimulant-induced mood disorder including amphetamines, methamphetamine or methcathinone
Stimulant-induced mood transtorno including amphetamines, methamphetamine and methcathinone is characterised by mood symptoms (e.g., depressed or elevated mood, decreased engagement in pleasurable activities, increased or decreased energy levels) that develop during or soon after intoxicação or abstinência due to stimulants. The intensity or duration of the symptoms is substantially in excess of mood disturbances that are characteristic of Stimulant intoxicação or Stimulant abstinência. The amount and duration of stimulant uso must be capable of producing mood symptoms. The symptoms are not better explained by a primary mental transtorno (e.g., a Depressive transtorno, a Bipolar transtorno, Transtorno esquizoafetivo), as might be the case if the mood symptoms preceded the onset of the stimulant uso, if the symptoms persist for a substantial period of time after cessation of the stimulant uso or abstinência, or if there is other evidence of a pre-existing primary mental transtorno com mood symptoms (e.g., a history of prior episodes not associated com uso of stimulants).
Stimulant-induced obsessive-compulsive or related disorder including amphetamines, methamphetamine or methcathinone
Stimulant-induced obsessive-compulsive or related transtorno including amphetamines, methamphetamine and methcathinone is characterised by either repetitive intrusive thoughts or preoccupations, normally associated com anxiety and typically accompanied by repetitive behaviours performed in response, or by recurrent and habitual actions directed at the integument (e.g., hair pulling, skin picking) that develop during or soon after intoxicação com or abstinência from stimulants. The intensity or duration of the symptoms is substantially in excess of analogous disturbances that are characteristic of Stimulant intoxicação or Stimulant abstinência. The amount and duration of stimulant uso must be capable of producing obsessive-compulsive or related symptoms. The symptoms are not better explained by a primary mental transtorno (in particular an Obsessive-compulsive or related transtorno), as might be the case if the symptoms preceded the onset of the stimulant uso, if the symptoms persist for a substantial period of time after cessation of the stimulant uso or abstinência, or if there is other evidence of a pre-existing primary mental transtorno com obsessive-compulsive or related symptoms (e.g., a history of prior episodes not associated com stimulant uso).
Stimulant-induced psychotic disorder including amphetamines but excluding caffeine or cocaine with mixed psychotic symptoms
Stimulant-induced psychotic transtorno com mixed psychotic symptoms is characterised by the presence of multiple psychotic symptoms, primarily hallucinations and delusions, when these are judged to be the direct consequence of stimulant uso. The symptoms do not occur exclusively during hypnogogic or hypnopompic states, are not better accounted for by another mental and behavioural transtorno (e.g., Esquizofrenia), and are not due to another transtorno or disease classified elsewhere (e.g., epilepsies com visual symptoms).
Stimulant-induced psychotic disorder including amphetamines, methamphetamine or methcathinone
Stimulant-induced psychotic transtorno including amphetamines, methamphetamine and methcathinone is characterised by psychotic symptoms (e.g., delusions, hallucinations, disorganised thinking, grossly disorganised behaviour) that develop during or soon after intoxicação or abstinência due to stimulants. The intensity or duration of the symptoms is substantially in excess of psychotic-like disturbances of perception, cognition, or behaviour that are characteristic of Stimulant intoxicação or Stimulant abstinência. The amount and duration of stimulant uso must be capable of producing psychotic symptoms. The symptoms are not better explained by a primary mental transtorno (e.g., Esquizofrenia, a Mood transtorno com psychotic symptoms), as might be the case if the psychotic symptoms preceded the onset of the stimulant uso, if the symptoms persist for a substantial period of time after cessation of the stimulant uso or abstinência, or if there is other evidence of a pre-existing primary mental transtorno com psychotic symptoms (e.g., a history of prior episodes not associated com uso of stimulants).
Stimulant-induced psychotic disorder including amphetamines, methamphetamine or methcathinone with delusions
Stimulant-induced psychotic transtorno including amphetamines, methamphetamine and methcathinone is characterised by psychotic symptoms (e.g., delusions, hallucinations, disorganised thinking, grossly disorganised behaviour) that develop during or soon after intoxicação or abstinência due to stimulants. The intensity or duration of the symptoms is substantially in excess of psychotic-like disturbances of perception, cognition, or behaviour that are characteristic of Stimulant intoxicação or Stimulant abstinência. The amount and duration of stimulant uso must be capable of producing psychotic symptoms. The symptoms are not better explained by a primary mental transtorno (e.g., Esquizofrenia, a Mood transtorno com psychotic symptoms), as might be the case if the psychotic symptoms preceded the onset of the stimulant uso, if the symptoms persist for a substantial period of time after cessation of the stimulant uso or abstinência, or if there is other evidence of a pre-existing primary mental transtorno com psychotic symptoms (e.g., a history of prior episodes not associated com uso of stimulants).
Stimulant-induced psychotic disorder including amphetamines, methamphetamine or methcathinone with hallucinations
Stimulant-induced psychotic transtorno com hallucinations is characterised by the presence of hallucinations that are judged to be the direct consequence of stimulant uso. Neither delusions nor other psychotic symptoms are present. The symptoms do not occur exclusively during hypnogogic or hypnopompic states, are not better accounted for by another mental and behavioural transtorno (e.g., Esquizofrenia), and are not due to another transtorno or disease classified elsewhere (e.g., epilepsies com visual symptoms).
Stress-related physiological response affecting disorders or diseases classified elsewhere
All diagnostic requirements for Psychological or behavioural factors affecting transtornos or diseases classified elsewhere are met. The individual exhibits stress-related physiological responses that adversely affect the manifestation, treatment, or course of a transtorno or disease classified in another chapter (e.g., stress-related exacerbation of ulcer, hypertension, arrhythmia, or tension headache).
Symptomatic and course presentations for mood episodes in mood disorders
These categories may be applied to describe the presentation and characteristics of mood episodes in the context of Episódio depressivo único, Transtorno depressivo recorrente, Transtorno bipolar tipo I, or Transtorno bipolar tipo II. These categories indicate the presence of specific, important features of the clinical presentation or of the course, onset, and padrão of mood episodes. These categories are not mutually exclusive, and as many may be added as apply.
Symptomatic manifestations of primary psychotic disorders
These categories may be used to characterize the atual clinical presentation in individuals diagnosed com Esquizofrenia or another primary psychotic transtorno, and should not be used in individuals sem such a diagnosis. Multiple categories may be applied. Symptoms attributable to the direct pathophysiological consequences of a health condition or injury not classified under Transtornos mentais, comportamentais ou do neurodesenvolvimento (e.g., a brain tumour or traumatic brain injury), or to the direct effects of a substance or medication on the central nervous system, including abstinência effects, should not be considered as examples of the respective types of symptoms.
Synthetic cannabinoid withdrawal
Synthetic cannabinoid abstinência is a clinically significant cluster of symptoms, behaviours and/or physiological features, varying in degree of severity and duration, that occurs upon cessation or reduction of uso of synthetic cannabinoids in individuals who have developed Synthetic cannabinoid dependência or have used synthetic cannabinoids for a prolonged period or in large amounts. Presenting features of Synthetic cannabinoid abstinência may include irritability, anger, aggression, shakiness, insomnia and disturbing dreams, restlessness, anxiety, depressed mood and appetite disturbance. In the early phase, Synthetic cannabinoid abstinência may be accompanied by residual features of intoxicação from the drug, such as paranoid ideation and auditory and visual hallucinations.
Synthetic cannabinoid dependence
Synthetic cannabinoid dependência is a transtorno of regulation of synthetic cannabinoid uso arising from repeated or continuous uso of synthetic cannabinoids. The characteristic feature is a strong internal drive to uso synthetic cannabinoids, which is manifested by impaired ability to control uso, increasing priority given to uso over other activities and persistence of uso despite harm or negative consequences. These experiences are often accompanied by a subjective sensation of urge or craving to uso synthetic cannabinoids. Physiological features of dependência may also be present, including tolerance to the effects of synthetic cannabinoids, abstinência symptoms following cessation or reduction in uso of synthetic cannabinoids, or repeated uso of synthetic cannabinoids or pharmacologically similar substances to prevent or alleviate abstinência symptoms. The features of dependência are usually evident over a period of at least 12 months but the diagnosis may be made if synthetic cannabinoid uso is continuous (daily or almost daily) for at least 3 months.
Synthetic cannabinoid dependence, current use
atual synthetic cannabinoid dependência com uso of synthetic cannabinoids within the past month.
Synthetic cannabinoid dependence, early full remission
After a diagnosis of synthetic cannabinoid dependência, and often following a treatment episódio or other intervention (including self-help intervention), the individual has been abstinent from synthetic cannabinoid uso during a period lasting between 1 and 12 months.
Synthetic cannabinoid dependence, sustained full remission
After a diagnosis of synthetic cannabinoid dependência, and often following a treatment episódio or other intervention (including self-intervention), the person has been abstinent from synthetic cannabinoid uso for 12 months or longer.
Synthetic cannabinoid dependence, sustained partial remission
After a diagnosis of synthetic cannabinoid dependência, and often following a treatment episódio or other intervention (including self-help intervention), there is a significant reduction in synthetic cannabinoid consumption for more than 12 months, such that even though synthetic cannabinoid uso has occurred during this period, the definitional requirements for dependência have not been met.
Synthetic cannabinoid intoxication
Synthetic cannabinoid intoxicação is a clinically significant transient condition that develops during or shortly after the consumption of synthetic cannabinoids that is characterised by disturbances in consciousness, cognition, perception, affect, behaviour, or coordination. These disturbances are caused by the known pharmacological effects of synthetic cannabinoids and their intensity is closely related to the amount of synthetic cannabinoid consumed. They are time-limited and abate as synthetic cannabinoid is cleared from the body. Presenting features may include inappropriate euphoria, impaired attention, impaired judgment, perceptual alterations (such as the sensation of floating, altered perception of time), changes in sociability, increased appetite, anxiety, intensification of ordinary experiences, impaired short-term memory, and sluggishness. Physical signs include conjunctival injection (red or bloodshot eyes) and tachycardia. intoxicação com synthetic cannabinoids may also cause Delirium or acute psychosis.
Synthetic cannabinoid-induced anxiety disorder
Synthetic cannabinoid-induced anxiety transtorno is characterised by anxiety symptoms (e.g., apprehension or worry, fear, physiological symptoms of excessive autonomic arousal, avoidance behaviour) that develop during or soon after intoxicação com or abstinência from synthetic cannabinoids. The intensity or duration of the symptoms is substantially in excess of anxiety symptoms that are characteristic of Synthetic cannabinoid intoxicação or Synthetic cannabinoid abstinência. The amount and duration of synthetic cannabinoid uso must be capable of producing anxiety symptoms. The symptoms are not better explained by a primary mental transtorno (e.g., an Anxiety and Fear-Related transtorno, a Depressive transtorno com prominent anxiety symptoms), as might be the case if the anxiety symptoms preceded the onset of the synthetic cannabinoid uso, if the symptoms persist for a substantial period of time after cessation of the synthetic cannabinoid uso or abstinência, or if there is other evidence of a pre-existing primary mental transtorno com anxiety symptoms (e.g., a history of prior episodes not associated com synthetic cannabinoid uso).
Synthetic cannabinoid-induced delirium
Synthetic cannabinoid-induced Delirium is characterised by an acute state of disturbed attention and awareness com specific features of Delirium that develops during or soon after substance intoxicação or abstinência or during the uso of synthetic cannabinoids. The amount and duration of synthetic cannabinoid uso must be capable of producing Delirium. The symptoms are not better explained by a primary mental transtorno, by uso of or abstinência from a different substance, or by another health condition that is not classified under Mental, behavioural and Transtornos do neurodesenvolvimento.
Synthetic cannabinoid-induced mood disorder
Synthetic cannabinoid-induced mood transtorno is characterised by mood symptoms (e.g., depressed or elevated mood, decreased engagement in pleasurable activities, increased or decreased energy levels) that develop during or soon after intoxicação com or abstinência from synthetic cannabinoids. The intensity or duration of the symptoms is substantially in excess of mood disturbances that are characteristic of Synthetic cannabinoid intoxicação or Synthetic cannabinoid abstinência. The amount and duration of synthetic cannabinoid uso must be capable of producing mood symptoms. The symptoms are not better explained by a primary mental transtorno (e.g., a Depressive transtorno, a Bipolar transtorno, Transtorno esquizoafetivo), as might be the case if the mood symptoms preceded the onset of the synthetic cannabinoid uso, if the symptoms persist for a substantial period of time after cessation of the synthetic cannabinoid uso or abstinência, or if there is other evidence of a pre-existing primary mental transtorno com mood symptoms (e.g., a history of prior episodes not associated com synthetic cannabinoid uso).
Synthetic cannabinoid-induced psychotic disorder
Synthetic cannabinoid-induced psychotic transtorno is characterised by psychotic symptoms (e.g., delusions, hallucinations, disorganised thinking, grossly disorganised behaviour) that develop during or soon after intoxicação com or abstinência from synthetic cannabinoids. The intensity or duration of the symptoms is substantially in excess of psychotic-like disturbances of perception, cognition, or behaviour that are characteristic of Synthetic cannabinoid intoxicação or Synthetic cannabinoid abstinência. The amount and duration of synthetic cannabinoid uso must be capable of producing psychotic symptoms. The symptoms are not better explained by a primary mental transtorno (e.g., Esquizofrenia, a Mood transtorno com psychotic symptoms), as might be the case if the psychotic symptoms preceded the onset of the synthetic cannabinoid uso, if the symptoms persist for a substantial period of time after cessation of the synthetic cannabinoid uso or abstinência, or if there is other evidence of a pre-existing primary mental transtorno com psychotic symptoms (e.g., a history of prior episodes not associated com synthetic cannabinoid uso).
Synthetic cathinone withdrawal
Synthetic cathinone abstinência is a clinically significant cluster of symptoms, behaviours and/or physiological features, varying in degree of severity and duration, that occurs upon cessation or reduction of uso of synthetic cathinones in individuals who have developed Synthetic cathinone dependência or have used synthetic cathinones for a prolonged period or in large amounts. Presenting features of Synthetic cathinone abstinência may include dysphoric mood, irritability, fatigue, insomnia or (more commonly) hypersomnia, vivid and unpleasant dreams, increased appetite, psychomotor agitation or retardation, and craving for stimulants, including synthetic cathinones.
Synthetic cathinone dependence
Synthetic cathinone dependência is a transtorno of regulation of synthetic cathinone uso arising from repeated or continuous uso of synthetic cathinones. The characteristic feature is a strong internal drive to uso synthetic cathinones, which is manifested by impaired ability to control uso, increasing priority given to uso over other activities and persistence of uso despite harm or negative consequences. These experiences are often accompanied by a subjective sensation of urge or craving to uso synthetic cathinones. Physiological features of dependência may also be present, including tolerance to the effects of synthetic cathinones, abstinência symptoms following cessation or reduction in uso of synthetic cathinones, or repeated uso of synthetic cathinones or pharmacologically similar substances to prevent or alleviate abstinência symptoms. The features of dependência are usually evident over a period of at least 12 months but the diagnosis may be made if synthetic cathinone uso is continuous (daily or almost daily) for at least 3 months.
Synthetic cathinone dependence, current use
atual synthetic cathinone dependência com uso of synthetic cathinones within the past month.
Synthetic cathinone dependence, early full remission
After a diagnosis of synthetic cathinone dependência, and often following a treatment episódio or other intervention (including self-help intervention), the individual has been abstinent from synthetic cathinone uso during a period lasting between 1 and 12 months.
Synthetic cathinone dependence, sustained full remission
After a diagnosis of synthetic cathinone dependência, and often following a treatment episódio or other intervention (including self-intervention), the person has been abstinent from synthetic cathinone uso for 12 months or longer.
Synthetic cathinone dependence, sustained partial remission
After a diagnosis of synthetic cathinone dependência, and often following a treatment episódio or other intervention (including self-help intervention), there is a significant reduction in synthetic cathinone consumption for more than 12 months, such that even though synthetic cathinone uso has occurred during this period, the definitional requirements for dependência have not been met.
Synthetic cathinone intoxication
Synthetic cathinone intoxicação is a clinically significant transient condition that develops during or shortly after the consumption of synthetic cathinones that is characterised by disturbances in consciousness, cognition, perception, affect, behaviour, or coordination. These disturbances are caused by the known pharmacological effects of synthetic cathinones and their intensity is closely related to the amount of synthetic cathinones consumed. They are time-limited and abate as the synthetic cathinone is cleared from the body. Presenting features may include anxiety, anger, impaired attention, hypervigilance, psychomotor agitation, paranoid ideation (possibly of delusional intensity), transient auditory hallucinations, transitory confusion, and changes in sociability. Perspiration or chills, nausea or vomiting, and palpitations may be experienced. Physical signs may include tachycardia, elevated blood pressure, pupillary dilatation, dyskinesias and dystonias, and skin sores. In rare instances, usually in grave intoxicação, uso of synthetic cathinones can result in seizures.
Synthetic cathinone-induced anxiety disorder
Synthetic cathinone-induced anxiety transtorno is characterised by anxiety symptoms (e.g., apprehension or worry, fear, physiological symptoms of excessive autonomic arousal, avoidance behaviour) that develop during or soon after intoxicação com or abstinência from synthetic cathinones. The intensity or duration of the symptoms is substantially in excess of anxiety symptoms that are characteristic of Synthetic cathinone intoxicação or Synthetic cathinone abstinência. The amount and duration of synthetic cathinone uso must be capable of producing anxiety symptoms. The symptoms are not better explained by a primary mental transtorno (e.g., an Anxiety and fear-related transtorno, a Depressive transtorno com prominent anxiety symptoms), as might be the case if the anxiety symptoms preceded the onset of the synthetic cathinone uso, if the symptoms persist for a substantial period of time after cessation of the synthetic cathinone uso or abstinência, or if there is other evidence of a pre-existing primary mental transtorno com anxiety symptoms (e.g., a history of prior episodes not associated com synthetic cathinone uso).
Synthetic cathinone-induced delirium
Synthetic cathinone-induced Delirium is characterised by an acute state of disturbed attention and awareness com specific features of Delirium that develops during or soon after substance intoxicação or abstinência or during the uso of synthetic cathinones. The amount and duration of synthetic cathinone uso must be capable of producing Delirium. The symptoms are not better explained by a primary mental transtorno, by uso of or abstinência from a different substance, or by another health condition that is not classified under Mental, behavioural and Transtornos do neurodesenvolvimento.
Synthetic cathinone-induced impulse control disorder
Synthetic cathinone-induced impulse control transtorno is characterised by persistently repeated behaviours in which there is recurrent failure to resist an impulse, drive, or urge to perform an act that is rewarding to the person, at least in the short-term, despite longer-term harm either to the individual or to others (e.g., fire setting or stealing sem apparent motive, repetitive sexual behaviour, aggressive outbursts) that develop during or soon after intoxicação com or abstinência from synthetic cathinones. The intensity or duration of the symptoms is substantially in excess of disturbances of impulse control that are characteristic of Synthetic cathinone intoxicação or Synthetic cathinone abstinência. The amount and duration of synthetic cathinone uso must be capable of producing disturbances of impulse control. The symptoms are not better explained by a primary mental transtorno (e.g., an Impulse control transtorno, a transtorno due to addictive behaviours), as might be the case if the impulse control disturbances preceded the onset of the synthetic cathinone uso, if the symptoms persist for a substantial period of time after cessation of the synthetic cathinone uso or abstinência, or if there is other evidence of a pre-existing primary mental transtorno com impulse control symptoms (e.g., a history of prior episodes not associated com synthetic cathinone uso).
Synthetic cathinone-induced mood disorder
Synthetic cathinone-induced mood transtorno is characterised by mood symptoms (e.g., depressed or elevated mood, decreased engagement in pleasurable activities, increased or decreased energy levels) that develop during or soon after intoxicação com or abstinência from synthetic cathinones. The intensity or duration of the symptoms is substantially in excess of mood disturbances that are characteristic of Synthetic cathinone intoxicação or Synthetic cathinone abstinência. The amount and duration of synthetic cathinone uso must be capable of producing mood symptoms. The symptoms are not better explained by a primary mental transtorno (e.g., a Depressive transtorno, a Bipolar transtorno, Transtorno esquizoafetivo), as might be the case if the mood symptoms preceded the onset of the synthetic cathinone uso, if the symptoms persist for a substantial period of time after cessation of the synthetic cathinone uso or abstinência, or if there is other evidence of a pre-existing primary mental transtorno com mood symptoms (e.g., a history of prior episodes not associated com synthetic cathinone uso).
Synthetic cathinone-induced obsessive-compulsive or related syndrome
Synthetic cathinone-induced obsessive-compulsive or related transtorno is characterised by either repetitive intrusive thoughts or preoccupations, normally associated com anxiety and typically accompanied by repetitive behaviours performed in response, or by recurrent and habitual actions directed at the integument (e.g., hair pulling, skin picking) that develop during or soon after intoxicação com or abstinência from synthetic cathinones. The intensity or duration of the symptoms is substantially in excess of analogous disturbances that are characteristic of Synthetic cathinone intoxicação or Synthetic cathinone abstinência. The amount and duration of synthetic cathinone uso must be capable of producing obsessive-compulsive or related symptoms. The symptoms are not better explained by a primary mental transtorno (in particular an Obsessive-compulsive or related transtorno), as might be the case if the symptoms preceded the onset of the synthetic cathinone uso, if the symptoms persist for a substantial period of time after cessation of the synthetic cathinone uso or abstinência, or if there is other evidence of a pre-existing primary mental transtorno com obsessive-compulsive or related symptoms (e.g., a history of prior episodes not associated com synthetic cathinone uso).
Synthetic cathinone-induced psychotic disorder
Synthetic cathinone-induced psychotic transtorno is characterised by psychotic symptoms (e.g., delusions, hallucinations, disorganised thinking, grossly disorganised behaviour) that develop during or soon after intoxicação com or abstinência from synthetic cathinones. The intensity or duration of the symptoms is substantially in excess of psychotic-like disturbances of perception, cognition, or behaviour that are characteristic of Synthetic cathinone intoxicação or Synthetic cathinone abstinência. The amount and duration of synthetic cathinone uso must be capable of producing psychotic symptoms. The symptoms are not better explained by a primary mental transtorno (e.g., Esquizofrenia, a Mood transtorno com psychotic symptoms), as might be the case if the psychotic symptoms preceded the onset of the synthetic cathinone uso, if the symptoms persist for a substantial period of time after cessation of the synthetic cathinone uso or abstinência, or if there is other evidence of a pre-existing primary mental transtorno com psychotic symptoms (e.g., a history of prior episodes not associated com synthetic cathinone uso).
Synthetic cathinone-induced psychotic disorder with delusions
Synthetic cathinone psychotic transtorno com delusions is characterised by the presence of delusions that are judged to be the direct consequence of synthetic cathinone uso. Neither hallucinations nor other psychotic symptoms are present. The symptoms do not occur exclusively during hypnogogic or hypnopompic states, are not better accounted for by another mental and behavioural transtorno (e.g., Esquizofrenia), and are not due to another transtorno or disease classified elsewhere (e.g., epilepsies com visual symptoms).
Synthetic cathinone-induced psychotic disorder with hallucinations
Synthetic cathinone-induced psychotic transtorno com hallucinations is characterised by the presence of hallucinations that are judged to be the direct consequence of synthetic cathinone uso. Neither delusions nor other psychotic symptoms are present. The symptoms do not occur exclusively during hypnogogic or hypnopompic states, are not better accounted for by another mental and behavioural transtorno (e.g., Esquizofrenia), and are not due to another transtorno or disease classified elsewhere (e.g., epilepsies com visual symptoms).
Synthetic cathinone-induced psychotic disorder with mixed psychotic symptoms
Synthetic cathinone-induced psychotic transtorno com mixed psychotic symptoms is characterised by the presence of multiple psychotic symptoms, primarily hallucinations and delusions, when these are judged to be the direct consequence of synthetic cathinone uso. The symptoms do not occur exclusively during hypnogogic or hypnopompic states, are not better accounted for by another mental and behavioural transtorno (e.g., Esquizofrenia), and are not due to another transtorno or disease classified elsewhere (e.g., epilepsies com visual symptoms).